Morgan Stanley Reiterates Overweight on Immunocore Hldgs, Maintains $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Andrew Galler has reiterated an Overweight rating on Immunocore Hldgs (NASDAQ:IMCR) and maintained a $79 price target.
July 17, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Immunocore Hldgs and maintained a $79 price target.
The Overweight rating from Morgan Stanley indicates a positive outlook for Immunocore Hldgs. The maintained price target of $79 suggests that the analyst believes the stock has potential for growth. This could have a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100